NCT04037995 Real World Study of End-stage Liver Disease in China
| NCT ID | NCT04037995 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Huashan Hospital |
| Condition | End Stage Liver DIsease |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2019-09-01 |
| Primary Completion | 2020-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2019-09-01 with a primary completion date of 2020-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aims of this study are exploring the current situation of end-stage liver disease in China, and the optimization of diagnosis and treatment. Liver cirrhosis often accompanied by a series of complications. Therefore, it is necessary to standardize the diagnosis and treatment of liver cirrhosis and its complications. End-stage liver disease mainly refers to the late stage of liver disease caused by various chronic liver damage. Its main feature is that liver function can not meet the physiological needs of human body. This study is a single-center, prospective and observational real-world study aimed at investigating and analyzing the current diagnosis and treatment of liver cirrhosis and end-stage liver disease in China.
Eligibility Criteria
Inclusion Criteria: 1. Informed consent of patients. 2. Diagnosis of any of the following diseases: acute decompensation of cirrhosis, chronic and acute liver failure, chronic liver failure and hepatocellular carcinoma (stage III-IV) Exclusion Criteria: 1. HIV antibody positive and AIDS patients 2. Serious psychiatric history, especially depression. Severe mental illness is defined as major depression or psychosis, suicide attempts, hospitalization due to mental illness or a period of disability due to mental illness. 3. Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs. 4. Patients with other malignant tumors (excluding those cured). 5. Pregnant, lactating women or women of childbearing age who are ready to conceive.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04037995 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying End Stage Liver DIsease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04037995 currently recruiting?
Yes, NCT04037995 is actively recruiting participants. Contact the research team at JINGWENAI1990@126.COM for enrollment information.
Where is the NCT04037995 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT04037995 clinical trial?
NCT04037995 is sponsored by Huashan Hospital. The trial plans to enroll 10,000 participants.